...
首页> 外文期刊>Clinical and Translational Allergy >The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow’s milk- and peanut allergy models
【24h】

The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow’s milk- and peanut allergy models

机译:口服和皮下抗原特异性免疫疗法在小鼠奶牛和花生过敏模型中的功效

获取原文
           

摘要

Background Antigen-specific immunotherapy (AIT) is a promising therapeutic approach for both cow’s milk allergy (CMA) and peanut allergy (PNA), but needs optimization in terms of efficacy and safety. Aim Compare oral immunotherapy (OIT) and subcutaneous immunotherapy (SCIT) in murine models for CMA and PNA and determine the dose of allergen needed to effectively modify parameters of allergy. Methods Female C3H/HeOuJ mice were sensitized intragastrically (i.g.) to whey or peanut extract with cholera toxin. Mice were treated orally (5?times/week) or subcutaneously (3 times/week) for three consecutive weeks. Hereafter, the acute allergic skin response, anaphylactic shock symptoms and body temperature were measured upon intradermal?(i.d.) and intraperitoneal?(i.p.) challenge, and mast cell degranulation was measured upon i.g. challenge. Allergen-specific IgE, IgG1 and IgG2a were measured in serum at different time points. Single cell suspensions derived from lymph organs were stimulated with allergen to induce cytokine production and T cell phenotypes were assessed using flow cytometry. Results Both OIT and SCIT decreased clinically related signs upon challenge in the CMA and PNA model. Interestingly, a rise in allergen-specific IgE was observed during immunotherapy, hereafter, treated mice were protected against the increase in IgE caused by allergen challenge. Allergen-specific IgG1 and IgG2a increased due to both types of AIT. In the CMA model, SCIT and OIT reduced the percentage of activated Th2 cells and increased the percentage of activated Th1 cells in the spleen. OIT increased the percentage of regulatory T cells (Tregs) and activated Th2 cells in the MLN. Th2 cytokines IL-5, IL-13 and IL-10 were reduced after OIT, but not after SCIT. In the PNA model, no differences were observed in percentages of T cell subsets. SCIT induced Th2 cytokines IL-5 and IL-10, whereas OIT had no effect. Conclusion We have shown clinical protection against allergic manifestations after OIT and SCIT in a CMA and PNA model. Although similar allergen-specific antibody patterns were observed, differences in T cell and cytokine responses were shown. Whether these findings are related to a different mechanism of AIT in CMA and PNA needs to be elucidated.
机译:背景技术抗原特异性免疫疗法(AIT)是一种对牛奶过敏(CMA)和花生过敏(PNA)都有希望的治疗方法,但是在功效和安全性方面需要进行优化。目的比较鼠模型中CMA和PNA的口服免疫疗法(OIT)和皮下免疫疗法(SCIT),并确定有效修改过敏参数所需的过敏原剂量。方法将雌性C3H / HeOuJ小鼠在胃内(例如)对含有霍乱毒素的乳清或花生提取物致敏。连续三个星期对小鼠进行口服(5次/周)或皮下(3次/周)治疗。此后,在皮内(i.d.)和腹膜内(i.p.)攻击时测量急性过敏性皮肤反应,过敏性休克症状和体温,并且在(i.g.)之后测量肥大细胞脱粒。挑战。在不同时间点在血清中测量过敏原特异性IgE,IgG1和IgG2a。用过敏原刺激衍生自淋巴器官的单细胞悬液,诱导细胞因子的产生,并使用流式细胞仪评估T细胞表型。结果在CMA和PNA模型中,OIT和SCIT均在受到挑战后降低了临床相关体征。有趣的是,在免疫治疗过程中观察到了过敏原特异性IgE的升高,此后,保护了处理过的小鼠免受由过敏原激发引起的IgE的升高。由于两种类型的AIT,过敏原特异性IgG1和IgG2a均增加。在CMA模型中,SCIT和OIT减少了脾脏中激活的Th2细胞百分比,并增加了激活的Th1细胞百分比。 OIT增加了MLN中调节性T细胞(Tregs)和激活的Th2细胞的百分比。 OIT后Th2细胞因子IL-5,IL-13和IL-10减少,而SCIT后则没有。在PNA模型中,未观察到T细胞亚群百分比的差异。 SCIT诱导Th2细胞因子IL-5和IL-10,而OIT没有作用。结论我们已经在CMA和PNA模型中显示了针对OIT和SCIT过敏性表现的临床保护。尽管观察到相似的过敏原特异性抗体模式,但显示了T细胞和细胞因子反应的差异。这些结果是否与CMA和PNA中AIT的不同机制相关,需要阐明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号